Modulation of doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates

Maria Grazia Refolo, Rosalba D’Alessandro, Catia Lippolis, Caterina Messa, Nicola Carella, Aldo Cavallini, Brian I. Carr

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Platelet extracts can stimulate cell growth and contribute to tumor biology. It was recently shown that they stimulate the growth of hepatocellular carcinoma (HCC) cells and decrease apoptosis. Doxorubicin is a commonly used HCC chemotherapy that increases apoptosis. We therefore examined the effects of platelet lysates (hPL) on doxorubicin-mediated HCC cell growth inhibition and apoptosis induction. Methods: Three human HCC cell lines, PLC/PRF/5, Hep3B and HepG2 cells, were grown in culture and growth was measured by the MTT assay and apoptosis was measured using Muse Annexin V assay kit. Cells were also probed by Western blot. Results: hPL decreased doxorubicin-mediated growth inhibition and apoptosis induction in all three cell lines. When doxorubicin and hPL were added at separate time intervals, protection by hPL was also observed. WB showed that hPL caused prolonged and increased levels of phospho-JNK and phospho-p38. Furthermore, a p38 inhibitor abrogated the modulating effects of hPL on both growth and apoptosis, indicating its importance in mediating hPL actions. WBs also showed that hPL decreased doxorubicin-induced markers of apoptosis. Conclusions: hPL modulate the actions of the cancer chemotherapeutic agent, doxorubicin. Platelets are part of the complex microenvironmental milieu and their effects may contribute to a modulation of chemotherapy actions. Conversely, drugs that alter platelet levels or degranulation could potentially augment doxorubicin actions on HCC cells.

Original languageEnglish
Pages (from-to)1154-1164
Number of pages11
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume14
Issue number8
Publication statusPublished - Sep 1 2014

Fingerprint

Doxorubicin
Hepatocellular Carcinoma
Blood Platelets
Apoptosis
Growth
Drug Therapy
Cell Line
Alprostadil
Annexin A5
Hep G2 Cells
Neoplasms
Western Blotting
Pharmaceutical Preparations

Keywords

  • Apoptosis
  • Autophagy
  • Cell growth
  • Doxorubicin
  • HCC
  • Platelets

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Modulation of doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates. / Refolo, Maria Grazia; D’Alessandro, Rosalba; Lippolis, Catia; Messa, Caterina; Carella, Nicola; Cavallini, Aldo; Carr, Brian I.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 14, No. 8, 01.09.2014, p. 1154-1164.

Research output: Contribution to journalArticle

@article{fbc52995506a4f329bc0cfb263cc3e07,
title = "Modulation of doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates",
abstract = "Purpose: Platelet extracts can stimulate cell growth and contribute to tumor biology. It was recently shown that they stimulate the growth of hepatocellular carcinoma (HCC) cells and decrease apoptosis. Doxorubicin is a commonly used HCC chemotherapy that increases apoptosis. We therefore examined the effects of platelet lysates (hPL) on doxorubicin-mediated HCC cell growth inhibition and apoptosis induction. Methods: Three human HCC cell lines, PLC/PRF/5, Hep3B and HepG2 cells, were grown in culture and growth was measured by the MTT assay and apoptosis was measured using Muse Annexin V assay kit. Cells were also probed by Western blot. Results: hPL decreased doxorubicin-mediated growth inhibition and apoptosis induction in all three cell lines. When doxorubicin and hPL were added at separate time intervals, protection by hPL was also observed. WB showed that hPL caused prolonged and increased levels of phospho-JNK and phospho-p38. Furthermore, a p38 inhibitor abrogated the modulating effects of hPL on both growth and apoptosis, indicating its importance in mediating hPL actions. WBs also showed that hPL decreased doxorubicin-induced markers of apoptosis. Conclusions: hPL modulate the actions of the cancer chemotherapeutic agent, doxorubicin. Platelets are part of the complex microenvironmental milieu and their effects may contribute to a modulation of chemotherapy actions. Conversely, drugs that alter platelet levels or degranulation could potentially augment doxorubicin actions on HCC cells.",
keywords = "Apoptosis, Autophagy, Cell growth, Doxorubicin, HCC, Platelets",
author = "Refolo, {Maria Grazia} and Rosalba D’Alessandro and Catia Lippolis and Caterina Messa and Nicola Carella and Aldo Cavallini and Carr, {Brian I.}",
year = "2014",
month = "9",
day = "1",
language = "English",
volume = "14",
pages = "1154--1164",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Modulation of doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates

AU - Refolo, Maria Grazia

AU - D’Alessandro, Rosalba

AU - Lippolis, Catia

AU - Messa, Caterina

AU - Carella, Nicola

AU - Cavallini, Aldo

AU - Carr, Brian I.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Purpose: Platelet extracts can stimulate cell growth and contribute to tumor biology. It was recently shown that they stimulate the growth of hepatocellular carcinoma (HCC) cells and decrease apoptosis. Doxorubicin is a commonly used HCC chemotherapy that increases apoptosis. We therefore examined the effects of platelet lysates (hPL) on doxorubicin-mediated HCC cell growth inhibition and apoptosis induction. Methods: Three human HCC cell lines, PLC/PRF/5, Hep3B and HepG2 cells, were grown in culture and growth was measured by the MTT assay and apoptosis was measured using Muse Annexin V assay kit. Cells were also probed by Western blot. Results: hPL decreased doxorubicin-mediated growth inhibition and apoptosis induction in all three cell lines. When doxorubicin and hPL were added at separate time intervals, protection by hPL was also observed. WB showed that hPL caused prolonged and increased levels of phospho-JNK and phospho-p38. Furthermore, a p38 inhibitor abrogated the modulating effects of hPL on both growth and apoptosis, indicating its importance in mediating hPL actions. WBs also showed that hPL decreased doxorubicin-induced markers of apoptosis. Conclusions: hPL modulate the actions of the cancer chemotherapeutic agent, doxorubicin. Platelets are part of the complex microenvironmental milieu and their effects may contribute to a modulation of chemotherapy actions. Conversely, drugs that alter platelet levels or degranulation could potentially augment doxorubicin actions on HCC cells.

AB - Purpose: Platelet extracts can stimulate cell growth and contribute to tumor biology. It was recently shown that they stimulate the growth of hepatocellular carcinoma (HCC) cells and decrease apoptosis. Doxorubicin is a commonly used HCC chemotherapy that increases apoptosis. We therefore examined the effects of platelet lysates (hPL) on doxorubicin-mediated HCC cell growth inhibition and apoptosis induction. Methods: Three human HCC cell lines, PLC/PRF/5, Hep3B and HepG2 cells, were grown in culture and growth was measured by the MTT assay and apoptosis was measured using Muse Annexin V assay kit. Cells were also probed by Western blot. Results: hPL decreased doxorubicin-mediated growth inhibition and apoptosis induction in all three cell lines. When doxorubicin and hPL were added at separate time intervals, protection by hPL was also observed. WB showed that hPL caused prolonged and increased levels of phospho-JNK and phospho-p38. Furthermore, a p38 inhibitor abrogated the modulating effects of hPL on both growth and apoptosis, indicating its importance in mediating hPL actions. WBs also showed that hPL decreased doxorubicin-induced markers of apoptosis. Conclusions: hPL modulate the actions of the cancer chemotherapeutic agent, doxorubicin. Platelets are part of the complex microenvironmental milieu and their effects may contribute to a modulation of chemotherapy actions. Conversely, drugs that alter platelet levels or degranulation could potentially augment doxorubicin actions on HCC cells.

KW - Apoptosis

KW - Autophagy

KW - Cell growth

KW - Doxorubicin

KW - HCC

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=84907164312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907164312&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 1154

EP - 1164

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 8

ER -